KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024)

AbCellera Biologics (ABCL) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $3.1 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Long-Term Debt Issuances fell 52.71% year-over-year to $3.1 million, compared with a TTM value of $14.2 million through Sep 2024, up 115.84%, and an annual FY2021 reading of $872000.0, down 94.37% over the prior year.
  • Long-Term Debt Issuances was $3.1 million for Q3 2024 at AbCellera Biologics, up from $2.4 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $16.2 million in Q1 2020 and bottomed at -$662000.0 in Q2 2020.
  • Average Long-Term Debt Issuances over 3 years is $3.7 million, with a median of $2.2 million recorded in 2024.
  • Peak annual rise in Long-Term Debt Issuances hit 52.71% in 2024, while the deepest fall reached 52.71% in 2024.
  • Year by year, Long-Term Debt Issuances stood at -$26000.0 in 2020, then surged by 25330.77% to $6.6 million in 2023, then tumbled by 52.71% to $3.1 million in 2024.
  • Business Quant data shows Long-Term Debt Issuances for ABCL at $3.1 million in Q3 2024, $2.4 million in Q2 2024, and $2.1 million in Q1 2024.